Best practice in placement of percutaneous endoscopic gastrostomy with jejunal extension tube for continuous infusion of levodopa carbidopa intestinal gel in the treatment of selected patients with Parkinson’s disease in the Nordic region

References

• Gauderer MW, Ponsky JL, Izant RJJr. Gastrostomy without laparotomy: a percutaneous endoscopic technique. J Pediatr Surg 1980;15:872–5.
   PubMed Web of Science ®Google Scholar
• Loser C, Aschl G, Hebuterne X, Mathus-Vliegen EM, Muscaritoli M, Niv Y, et al. ESPEN guidelines on artificial enteral nutrition--percutaneous endoscopic gastrostomy (PEG). Clin Nutr 2005;24:848–61.
   PubMed Web of Science ®Google Scholar
• Kirby DF, Delegge MH, Fleming CR. American Gastroenterological Association technical review on tube feeding for enteral nutrition. Gastroenterology 1995;108:1282–301.
   PubMed Web of Science ®Google Scholar
• Ponsky JL, Aszodi A. Percutaneous endoscopic jejunostomy. Am J Gastroenterol 1984;79:113–16.
   PubMed Web of Science ®Google Scholar
• Nilsson D, Hansson LE, Johansson K, Nystrom C, Paalzow L, Aquilonius SM. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson’s disease. Acta Neurol Scand 1998;97:175–83.
   PubMed Web of Science ®Google Scholar
• Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson’s disease. CMAJ 2003;168:293–301.
   PubMed Web of Science ®Google Scholar
• Marttila RJ, Rinne UK. Epidemiology of Parkinson’s disease in Finland. Acta Neurol Scand 1976;53:81–102.
   PubMed Web of Science ®Google Scholar
• Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA. The epidemiology of Parkinson’s disease in the county of Rogaland, Norway. Mov Disord 1995;10:541–9.
   PubMed Web of Science ®Google Scholar
• Fall PA, Axelson O, Fredriksson M, Hansson G, Lindvall B, Olsson JE, et al. Age-standardized incidence and prevalence of Parkinson’s disease in a Swedish community. J Clin Epidemiol 1996;49:637–41.
   PubMed Web of Science ®Google Scholar
• Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Changing epidemiology of Parkinson’s disease in southwestern Finland. Neurology 1999;52:302–8.
   PubMed Web of Science ®Google Scholar
• Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 2011;26:S1–58.
   PubMed Web of Science ®Google Scholar
• Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson’s disease. CNS Drugs 2010;24:119–29.
   PubMed Web of Science ®Google Scholar
• Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs 1998;55:1–9.
   PubMed Web of Science ®Google Scholar
• Lundqvist C. Continuous levodopa for advanced Parkinson’s disease. Neuropsychiatr Dis Treat 2007;3:335–48.
   PubMedGoogle Scholar
• Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernas H, Nystrom C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156–63.
   PubMed Web of Science ®Google Scholar
• Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 1999;56:529–35.
   PubMed Web of Science ®Google Scholar
• Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47:S2–9; discussion S-11.
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med 1998;339:1044–53.
   PubMed Web of Science ®Google Scholar
• Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet 1977;309:345–9.
   Google Scholar
• Olanow CW, Obeso JA, Stocchi F. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Nat Clin Pract Neurol 2006;2:382–92.
   PubMedGoogle Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677–87.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Rizos A, Sethi KD. Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery? J Neural Transm 2013;120:1305–20.
   PubMed Web of Science ®Google Scholar
• Hauser RA. Levodopa: past, present, and future. Eur Neurol 2009;62:1–8.
   PubMed Web of Science ®Google Scholar
• Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease. Expert Rev Neurother 2006;6:1403–11.
   PubMedGoogle Scholar
• Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, et al. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord 2007;22:1145–9.
   PubMed Web of Science ®Google Scholar
• Eggert K, Schrader C, Hahn M, Stamelou M, Russmann A, Dengler R, et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151–66.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: Final 12-month, open-label results. Mov Disord 2015;30:500–9.
   PubMed Web of Science ®Google Scholar
• Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson’s disease--long-term experience. Acta Neurol Scand 2001;104:343–8.
   PubMed Web of Science ®Google Scholar
• Nyholm D, Jansson R, Willows T, Remahl IN. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 2005;65:1506–7.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13:141–9.
   PubMed Web of Science ®Google Scholar
• Puente V, De Fabregues O, Oliveras C, Ribera G, Pont-Sunyer C, Vivanco R, et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson’s disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 2010;16:218–21.
   PubMed Web of Science ®Google Scholar
• Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson’s disease patients. J Parkinsons Dis 2015;5:165–74.
   PubMedGoogle Scholar
• Kwon RS, Banerjee S, Desilets D, Diehl DL, Farraye FA, Kaul V, et al. Enteral nutrition access devices. Gastrointest Endosc 2010;72:236–48.
   PubMed Web of Science ®Google Scholar
• AbbVie. PEG: Percutaneous endoscopic gastrostomy kit 15FR/20FR instructions for use. 2014. Available from http://www.rxabbvie.com/pdf/abbvie_instr_pegtube.pdf. [Cited 12 May 2015].
   Google Scholar
• Committee ASoP. Levy MJ, Anderson MA, Baron TH, Banerjee S, Dominitz JA, et al. Position statement on routine laboratory testing before endoscopic procedures. Gastrointest Endosc 2008;68:827–32.
   PubMed Web of Science ®Google Scholar
• Boustiere C, Veitch A, Vanbiervliet G, Bulois P, Deprez P, Laquiere A, et al. Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2011;43:445–61.
   PubMed Web of Science ®Google Scholar
• Blomberg J, Lagergren P, Martin L, Mattsson F, Lagergren J. Novel approach to antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG): randomised controlled trial. BMJ 2010;341:c3115.
   PubMed Web of Science ®Google Scholar
• Lipp A, Lusardi G. Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy. Cochrane Database Syst Rev 2006;CD005571.
   Google Scholar
• Metheny N, Eisenberg P, McSweeney M. Effect of feeding tube properties and three irrigants on clogging rates. Nurs Res 1988;37:165–9.
   PubMed Web of Science ®Google Scholar
• Reising DL, Neal RS. Enteral tube flushing. Am J Nurs 2005;105:58–63; quiz -4.
   PubMed Web of Science ®Google Scholar
• AbbVie. Duodopa Intestinal Gel summary of product characteristics. 2014. Available from http://www.medicines.org.uk/emc/medicine/20786. [Cited 12 May 2015].
   Google Scholar
• Zopf Y, Konturek P, Nuernberger A, Maiss J, Zenk J, Iro H, et al. Local infection after placement of percutaneous endoscopic gastrostomy tubes: a prospective study evaluating risk factors. Can J Gastroenterol 2008;22:987–91.
   PubMed Web of Science ®Google Scholar
• Chung RS, Schertzer M. Pathogenesis of complications of percutaneous endoscopic gastrostomy. A lesson in surgical principles. Am Surg 1990;56:134–7.
   PubMed Web of Science ®Google Scholar